Niowave announced the expansion of its existing supply agreement with AstraZeneca (AZN) to a 10-year commitment to deliver Actinium-225 following AstraZeneca’s decision to exercise its option to increase capacity. “The agreement secures a reliable and scalable supply of this critical isotope to advance AstraZeneca’s growing portfolio of radioconjugates,” a type of cancer treatment that use radioactive particles to target and destroy cancer cells, Niowave said.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- TROPION-Lung17: New Phase III Lung Cancer Trial Adds Medium-Term Upside Potential for AstraZeneca and Daiichi Sankyo
- AstraZeneca Targets Costly C. Diff Recurrence With New Antibody Trial
- AstraZeneca’s AZD1163 Trial Adds Quiet Option Value in Rheumatoid Arthritis
- AstraZeneca’s AZD5004 Obesity Trial Edges Forward, Raising New Questions for Investors
- AstraZeneca Strengthens China Rare-Disease Position With New Real-World PNH Study Update